Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
STAT13d
Eli Lilly is considering offering more Zepbound doses in vials at lower cost
When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...
Forbes27d
Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver
In this photo is a Zepbound injection pen arranged in the Brooklyn borough ... The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers ...
Morgan Stanley Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...
pharmaphorum7d
Lilly preps for rollout of its connected diabetes system
After years of preparation, Eli Lilly is ... data from the pen, and can link with compatible devices. That includes continuous glucose monitoring systems developed by Lilly's partner Dexcom ...